A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2013

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Social isolation
  • Focus Registrational; Therapeutic Use
  • Acronyms Harbor-A; TESSA
  • Most Recent Events

    • 01 Oct 2012 Planned End Date changed from 1 Jul 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top